Bio-Techne Corporation (TECH)TECHBio-Techne Corporation

Financials

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	1.21B	311.42M	295.88M	286.56M	316.96M	316.18M	297.03M	289.46M	306.10M
Cost of Goods Sold	424.32M	103.13M	104.60M	98.44M	118.15M	101.63M	103.14M	106.44M	102.75M
Gross Profit	786.49M	208.29M	191.28M	188.11M	198.81M	214.56M	193.89M	183.02M	203.35M
Gross Profit Margin	65.0%	66.9%	64.6%	65.6%	62.7%	67.9%	65.3%	63.2%	66.4%
Total Operating Expenses	632.74M	132.79M	136.82M	140.45M	222.67M	175.85M	146.47M	143.03M	157.53M
Research & Development	96.85M	23.45M	23.13M	24.24M	26.03M	24.58M	25.02M	23.87M	23.99M
Selling, General & Administrative	362.46M	109.34M	113.69M	116.21M	23.22M	151.27M	121.45M	119.16M	60.48M
Operating Income (EBIT)	153.75M	75.50M	54.46M	47.66M	-23.86M	38.71M	47.42M	39.99M	45.82M
Operating Margin	12.7%	24.2%	18.4%	16.6%	-7.5%	12.2%	16.0%	13.8%	15.0%
Income Before Tax (EBT)	147.14M	71.22M	50.78M	47.99M	-22.86M	38.27M	42.88M	40.17M	41.66M
Interest Income	3.43M	981K	897K	971K	585K	1.03M	1.35M	926K	905K
Interest Expense	10.51M	3.22M	2.17M	2.93M	2.18M	2.01M	2.15M	2.18M	2.51M
Other Income/Expense	-6.61M	-4.27M	-3.68M	333K	1.00M	-434K	-4.54M	184K	-4.16M
Net Income	109.57M	51.06M	38.01M	38.19M	-17.68M	22.59M	34.89M	33.60M	40.59M
Income Tax Expense	37.58M	20.18M	12.78M	9.81M	-5.18M	15.69M	7.99M	6.57M	1.07M
Net Profit Margin	9.0%	16.4%	12.8%	13.3%	-5.6%	7.1%	11.7%	11.6%	13.3%
EBITDA	254.08M	99.66M	79.17M	72.00M	3.25M	66.28M	74.50M	68.12M	73.88M
EBITDA Margin	21.0%	32.0%	26.8%	25.1%	1.0%	21.0%	25.1%	23.5%	24.1%
Depreciation & Amortization	100.33M	24.17M	24.71M	24.34M	27.11M	27.57M	27.08M	28.14M	28.06M
EPS Basic	0.71	0.33	0.24	0.25	-0.11	0.14	0.22	0.21	0.26
EPS Diluted	0.69	0.32	0.24	0.24	-0.11	0.14	0.22	0.21	0.25
Shares Outstanding	155.89M	155.89M	155.84M	155.46M	154.91M	157.37M	158.43M	158.53M	157.87M
Diluted Shares Outstanding	156.94M	156.94M	157.00M	156.36M	155.76M	158.94M	160.63M	161.12M	160.65M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021	06/30/2020	06/30/2019	06/30/2018
Revenue	1.22B	1.16B	1.14B	1.11B	931.03M	738.69M	714.01M	642.99M
Cost of Goods Sold	429.36M	389.33M	366.89M	349.10M	298.18M	255.50M	240.51M	210.85M
Gross Profit	790.27M	769.73M	769.82M	756.50M	632.85M	483.19M	473.49M	432.14M
Gross Profit Margin	64.8%	66.4%	67.7%	68.4%	68.0%	65.4%	66.3%	67.2%
Total Operating Expenses	688.02M	563.04M	470.87M	459.91M	395.55M	325.77M	326.77M	295.96M
Research & Development	99.50M	96.66M	92.49M	87.14M	70.60M	65.19M	62.41M	55.33M
Selling, General & Administrative	415.10M	393.32M	352.44M	339.00M	289.92M	240.88M	264.36M	240.64M
Operating Income (EBIT)	102.25M	206.69M	298.94M	296.59M	237.30M	157.42M	125.58M	136.18M
Operating Margin	8.4%	17.8%	26.3%	26.8%	25.5%	21.3%	17.6%	21.2%
Income Before Tax (EBT)	98.46M	185.69M	338.66M	301.39M	148.18M	276.48M	112.02M	125.95M
Interest Income	3.89M	3.32M	3.41M	794K	473K	605K	569K	409K
Interest Expense	8.51M	15.74M	11.21M	11.31M	13.95M	19.20M	21.70M	10.19M
Other Income/Expense	-3.79M	-21.00M	39.72M	4.80M	-89.12M	119.06M	-34.70M	-10.23M
Net Income	73.40M	168.10M	285.26M	272.05M	140.41M	229.30M	96.07M	125.35M
Income Tax Expense	25.06M	17.58M	53.22M	38.29M	8.59M	47.18M	15.94M	-602K
Net Profit Margin	6.0%	14.5%	25.1%	24.6%	15.1%	31.0%	13.5%	19.5%
EBITDA	212.16M	318.40M	406.18M	397.66M	325.04M	240.16M	203.75M	200.64M
EBITDA Margin	17.4%	27.5%	35.7%	36.0%	34.9%	32.5%	28.5%	31.2%
Depreciation & Amortization	109.90M	111.71M	107.24M	101.07M	87.75M	82.74M	78.17M	64.46M
EPS Basic	0.47	1.07	1.81	1.73	0.91	1.50	0.64	0.84
EPS Diluted	0.46	1.05	1.76	1.66	0.87	1.45	0.62	0.82
Shares Outstanding	157.52M	157.71M	157.18M	156.88M	154.99M	152.80M	151.12M	149.90M
Diluted Shares Outstanding	159.72M	160.77M	161.85M	164.12M	161.93M	157.60M	155.57M	152.22M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN

3,100 employees

www.bio-techne.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kim Kelderman

View full financials